2010
DOI: 10.1016/j.pharmthera.2010.04.010
|View full text |Cite
|
Sign up to set email alerts
|

Therapeutic anti-inflammatory potential of formyl-peptide receptor agonists

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
83
0
1

Year Published

2011
2011
2018
2018

Publication Types

Select...
9
1

Relationship

2
8

Authors

Journals

citations
Cited by 103 publications
(85 citation statements)
references
References 182 publications
1
83
0
1
Order By: Relevance
“…Considering the present model of CPIP induced by I/R, these founds are also in agreement with the idea that targeting ALX/FPR2 receptors in both types of cells can be useful to treat symptoms of diseases in which pathophysiology relies importantly on vascular disturbances Dufton & Perretti, 2010), specially those involving I/R-induced injuries (Gavins, 2010).…”
Section: Discussionsupporting
confidence: 91%
“…Considering the present model of CPIP induced by I/R, these founds are also in agreement with the idea that targeting ALX/FPR2 receptors in both types of cells can be useful to treat symptoms of diseases in which pathophysiology relies importantly on vascular disturbances Dufton & Perretti, 2010), specially those involving I/R-induced injuries (Gavins, 2010).…”
Section: Discussionsupporting
confidence: 91%
“…The formylated methionyl has been regarded as a key residue for the interaction of microbial peptides with the classic formyl peptide receptor (FPR1) (34,37), and it is fully logical that chemical alterations in this part of the molecule should affect the receptor-binding characteristics and by that the function of peptides that bind FPR2. With respect to the receptor involved, it is of special interest that the innate immune system senses peptide toxins through FPR2, a receptor earlier described to be primarily a target for new anti-inflammatory strategies (18,39). The structural basis for PSM␣ inactivation is not known, but other critical amino acids (besides methionine) represent possible targets for oxidative inactivation.…”
Section: Discussionmentioning
confidence: 99%
“…Agonists as well as antagonists for FPR2 have been suggested to be of therapeutic value [36,37], and in addition, if they in one way or another selectively stimulate/inhibit neutrophil functions, they may be used also as research tools [5]. In order to find agonists with this potency, we screened a library of small compounds and several ligands for FPR2 with varying EC 50 values were identified.…”
Section: Discussionmentioning
confidence: 99%